Health - Latest News Search Engine - Global and Local Breaking News

Health

Sectra's year-end report 2024/2025: Reporting solid growth in a time of change

LINKÖPING, Sweden, June 5, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) is continuing to deliv...

Sectra's year-end report 2024/2025: Reporting solid growth in a time of change

Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany

MELBOURNE, Australia, June 5, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces that ...

Telix's Illuccix® PSMA-PET Imaging Agent Approved in Germany

Hopes 'game-changing find' could ease chronic pain

Marlene Lowe is among those helping University of Aberdeen researchers to help millions of sufferers.

Hopes 'game-changing find' could ease chronic pain

Greater awareness not more cases behind ADHD surge, study suggests

Study found no evidence of significant rise with jump in demand for help down to under-diagnosis.

Greater awareness not more cases behind ADHD surge, study suggests

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers | Valuates Reports

Anticancer Drugs Market is Segmented by Type (Cancer Immunotherapy, Targeted Therapy, Chemotherapy), by Application (Lung Cancer, Breast Cancer, Prost...

Global Anticancer Drugs Market Booms with 11.3% CAGR, Driven by Targeted Therapy & Biomarkers | Valuates Reports

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

BEIJING, June 5, 2025 /PRNewswire/ -- Tsingke Biotech recently participated in TIDES USA 2025, the leading international event for oligonucleotide and...

Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

SHANGHAI and CHICAGO, June 5, 2025 /PRNewswire/ -- The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HK...

Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Next-generation technologies will help increase the agility and efficiency of genetic sequencing to tackle several diseases SAO PAULO, June 5, 2025 /P...

MGI Tech Expands Partnership with Fiocruz to Accelerate Advances in Epidemiological Surveillance and Personalized Medicine in Brazil

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indi...

HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Adm...

Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

HENDERSON, Nevada, June 4, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today ann...

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

First bacteria we ever meet can keep us out of hospital

For the first time, scientists show how our microbiome forms affects the risk of infection.

First bacteria we ever meet can keep us out of hospital

Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squa...

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical com...

Innovent's IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Receives Second NMPA Breakthrough Therapy Designation for Immuno-resistant Squamous Non-Small Cell Lung Cancer

Astellas wählt Veeva Vault CRM als globalen Standard

Vault CRM wird Astellas' geschäftliche Agilität und Ausführung unterstützen. PLEASANTON, Kalif. (USA), 5. Juni 2025 /PRNewswire/ -- Veeva Systems (NYS...

Astellas wählt Veeva Vault CRM als globalen Standard

Pregnant women warned against using weight-loss jabs

Women also reminded that they should use the most effective contraception to avoid pregnancy while taking 'skinny jabs'.

Pregnant women warned against using weight-loss jabs

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell C...

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical com...

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma

Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding

AMED grant to support the clinical development of RM-0256 photoimmunotherapy for targeting malignant epithelial tumors Targeting PD-L1, pre-clinical o...

Rakuten Medical's Anti-PD-L1 Antibody-IR700 Conjugate, RM-0256, Selected for AMED Funding

Astellas choisit Vault CRM de Veeva comme norme mondiale

Vault CRM soutiendra l'agilité commerciale et l'exécution d'Astellas PLEASANTON, Calif., 5 juin 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) a anno...

Astellas choisit Vault CRM de Veeva comme norme mondiale

Congrès de l'ERA : Les données à long terme montrent une efficacité et une sécurité durables de zigakibart chez les patients atteints de néphropathie ...

VIENNE, 5 juin 2025 /PRNewswire/ -- Les nouvelles données à 100 semaines de l'étude de phase 1/2 en cours sur zigakibart, un anticorps monoclonal anti...

Congrès de l'ERA : Les données à long terme montrent une efficacité et une sécurité durables de zigakibart chez les patients atteints de néphropathie à IgA

Congreso ERA: eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía IgA

-Congreso ERA: Datos a largo plazo muestran la eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía IgA VIENA, 5 de junio de 2025...

Congreso ERA: eficacia y seguridad sostenidas de zigakibart en pacientes con nefropatía IgA

ERA Congress: Langfristige Daten zeigen nachhaltige Wirksamkeit und Sicherheit von zigakibart bei Patienten mit IgA-Nephropathie

WIEN, 5. Juni 2025 /PRNewswire/ -- Neue 100-Wochen-Daten aus der laufenden Phase-1/2-Studie von zigakibart, einem monoklonalen Anti-APRIL-Antikörper, ...

ERA Congress: Langfristige Daten zeigen nachhaltige Wirksamkeit und Sicherheit von zigakibart bei Patienten mit IgA-Nephropathie